Assembly Biosciences, Inc.

NASDAQ:ASMB

Biotechnology

Healthcare
$22.39 +0.66%

+$0.16 today

Market cap
$458.48M
Beta
1.08
P/E (TTM)
-64.4
EPS (TTM)
-$0.38
52W Low $16.50High $39.71

Volume 0.49M

Average 0.17M

ASMB Pre-Tax Margin

Income before tax as a percentage of revenue.

Assembly Biosciences, Inc.NASDAQ: ASMB

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -110.5%

Pre-tax margin was -110.5% in Q1 FY2026, down 16.9 pp from a year earlier. On a trailing-twelve-month basis it was -9.0%, up 113.7 pp year over year.

Context

  • Pre-tax margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-110.5%-162.6 pp QoQ
Last fiscal yearDec 2025
-8.5%+131.2 pp YoY
LTMMar 2026
-9.0%+113.7 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-16.9 pp——
1 year+131.2 pp——
3 years———
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-8.5%
Year-over-year change
+131.2pp

Pre-Tax Margin vs competitors

How ASMB compares with its peers on the latest reported figures

  • ASMB's LTM Mar 2026 pre-tax margin of -9.0% is the 2nd highest of the 4 companies compared; the peer median is -89.4%.
  • Its year-over-year change of +113.7 pp is the 3rd highest of 4, against a peer median of +1279.8 pp.
ASMB Competitors Peer median
Pre-Tax Margin for ASMB and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 202684.0% +1279.8 pp-71.3 pp
ASMBAssembly Biosciences, Inc.LTM Mar 2026-9.0% +113.7 pp—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026-89.4% +64.0 pp+13.9 pp
VIRVir Biotechnology, Inc.LTM Mar 2026-675.4% +2100.4 pp-685.2 pp
INDPIndaptus Therapeutics, Inc.FY2025— ——
AVIRAtea Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ASMB) -89.4%+1279.8 pp-71.3 pp

Competitors are the stored peer set for ASMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.25M07.16M28.52M72.3M
Cost of Revenue069.08M48.9M55.93M129K
Gross Profit6.25M(69.08M)(41.74M)(27.41M)72.17M
Gross Margin100.0%—-582.7%-96.1%99.8%
Research & Development68.52M69.98M48.9M55.93M64.81M
Selling, General & Admin28.78M23.93M22.91M18.01M19.61M
Operating Expenses138.94M25.03M22.91M18.01M84.42M
Depreciation & Amortization466K498K450K129K129K
EBITDA(90.58M)(92.52M)(60.75M)(39.72M)(5.99M)
EBITDA Margin-1448.4%—-848.0%-139.3%-8.3%
Operating Income(132.69M)(94.11M)(64.65M)(45.42M)(12.12M)
Operating Margin-2121.7%—-902.5%-159.3%-16.8%
Interest Income302K1.02M3.45M5.57M6M
Interest Expense00000
Other Income / Expenses302K1.02M3.45M5.57M6M
Income Before Tax(132.39M)(93.09M)(61.2M)(39.85M)(6.12M)
Pre-Tax Margin-2116.8%—-854.3%-139.7%-8.5%
Income Tax Expense(2.53M)033K330K0
Net Income(129.86M)(93.09M)(61.23M)(40.18M)(6.12M)
Net Margin-2076.4%—-854.8%-140.9%-8.5%
EPS (Basic)(36.00)(22.82)(13.38)(6.69)(0.55)
EPS (Diluted)(36.00)(22.82)(13.38)(6.69)(0.55)
Weighted Avg Shares3.61M4.03M4.58M6M11.21M
Weighted Avg Shares (Diluted)3.61M4.03M4.58M6M11.21M

Assembly Biosciences, Inc.

NASDAQ:ASMB

Intrinsic Alpha fair value

Locked

Current Price

$22.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.